Insider Selling: Scholar Rock (NASDAQ:SRRK) Director Sells 1,006 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Katie Peng sold 1,006 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $44.09, for a total transaction of $44,354.54. Following the transaction, the director owned 32,908 shares of the company’s stock, valued at approximately $1,450,913.72. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Scholar Rock Price Performance

SRRK stock traded down $1.08 during trading on Thursday, hitting $42.93. The stock had a trading volume of 1,162,934 shares, compared to its average volume of 1,642,762. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $48.28. The company’s 50-day moving average price is $36.32 and its two-hundred day moving average price is $35.34. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The stock has a market capitalization of $4.38 billion, a P/E ratio of -13.63 and a beta of 0.61.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter last year, the business earned ($0.66) earnings per share. As a group, research analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Institutional Trading of Scholar Rock

Several hedge funds have recently made changes to their positions in the company. Ramirez Asset Management Inc. acquired a new stake in shares of Scholar Rock during the 3rd quarter worth approximately $37,000. Penserra Capital Management LLC purchased a new position in Scholar Rock in the third quarter worth approximately $56,000. Bessemer Group Inc. increased its stake in Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock worth $86,000 after acquiring an additional 2,105 shares during the last quarter. Strs Ohio acquired a new stake in Scholar Rock during the first quarter worth $77,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in Scholar Rock in the second quarter valued at $94,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on SRRK shares. HC Wainwright decreased their price objective on Scholar Rock from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Wolfe Research started coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price for the company. Leerink Partners began coverage on shares of Scholar Rock in a research note on Monday, September 15th. They issued an “outperform” rating and a $51.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Four equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $48.92.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.